MARKSANS PHARMA
|
MARKSANS PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 6.92 | 5.88 | 4.51 | 5.76 | 2.86 |
| CEPS(Rs) | 8.59 | 7.00 | 5.66 | 6.71 | 3.60 |
| DPS(Rs) | 0.60 | 0.50 | 0.25 | 0.25 | 0.10 |
| Book NAV/Share(Rs) | 45.57 | 38.51 | 27.10 | 21.66 | 15.54 |
| Tax Rate(%) | 25.65 | 21.42 | 24.52 | 21.06 | 23.17 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 20.03 | 16.64 | 16.71 | 24.40 | 16.95 |
| EBIT Margin(%) | 18.99 | 17.00 | 16.53 | 22.28 | 14.63 |
| Pre Tax Margin(%) | 18.50 | 16.56 | 15.98 | 21.71 | 13.86 |
| PAT Margin (%) | 13.75 | 13.01 | 12.06 | 17.14 | 10.65 |
| Cash Profit Margin (%) | 17.00 | 15.55 | 14.95 | 19.74 | 13.00 |
| Performance Ratios | |||||
| ROA(%) | 12.93 | 13.78 | 12.94 | 22.40 | 14.17 |
| ROE(%) | 16.53 | 18.59 | 18.72 | 31.33 | 20.49 |
| ROCE(%) | 22.40 | 22.89 | 23.82 | 39.76 | 25.57 |
| Asset Turnover(x) | 0.94 | 1.06 | 1.07 | 1.31 | 1.33 |
| Sales/Fixed Asset(x) | 2.26 | 2.62 | 2.42 | 2.49 | 2.12 |
| Working Capital/Sales(x) | 1.55 | 1.53 | 1.83 | 2.30 | 3.11 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.44 | 0.38 | 0.41 | 0.40 | 0.47 |
| Receivable days | 69.35 | 72.63 | 78.56 | 67.57 | 67.57 |
| Inventory Days | 87.89 | 81.36 | 97.65 | 84.73 | 86.10 |
| Payable days | 87.70 | 85.31 | 93.88 | 85.57 | 69.55 |
| Valuation Parameters | |||||
| PER(x) | 21.89 | 11.99 | 10.10 | 8.67 | 4.86 |
| PCE(x) | 17.65 | 10.07 | 8.05 | 7.44 | 3.86 |
| Price/Book(x) | 3.33 | 1.83 | 1.68 | 2.31 | 0.89 |
| Yield(%) | 0.40 | 0.71 | 0.55 | 0.50 | 0.72 |
| EV/Net Sales(x) | 2.86 | 1.36 | 1.04 | 1.35 | 0.44 |
| EV/Core EBITDA(x) | 12.23 | 6.32 | 5.18 | 5.35 | 2.57 |
| EV/EBIT(x) | 14.32 | 7.27 | 6.08 | 5.97 | 2.98 |
| EV/CE(x) | 2.97 | 1.41 | 0.94 | 1.51 | 0.55 |
| M Cap / Sales | 3.15 | 1.72 | 1.25 | 1.49 | 0.50 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 17.56 | 24.23 | 8.33 | 21.33 | 13.41 |
| Core EBITDA Growth(%) | 27.69 | 32.55 | -13.16 | 79.82 | 40.81 |
| EBIT Growth(%) | 25.36 | 35.48 | -17.47 | 86.93 | 45.59 |
| PAT Growth(%) | 18.68 | 42.02 | -21.68 | 97.54 | 50.12 |
| EPS Growth(%) | 17.80 | 30.32 | -21.77 | 101.63 | 53.05 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | 0.02 | 0.04 | 0.02 | 0.03 |
| Current Ratio(x) | 4.78 | 4.91 | 3.22 | 3.02 | 2.59 |
| Quick Ratio(x) | 3.19 | 3.49 | 2.11 | 1.67 | 1.54 |
| Interest Cover(x) | 38.80 | 37.99 | 30.31 | 38.84 | 18.97 |
| Total Debt/Mcap(x) | - | 0.01 | 0.02 | 0.01 | 0.03 |
Compare Financial Ratios of peers of MARKSANS PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MARKSANS PHARMA | ₹13,761.4 Cr | -2.7% | -1.7% | 97.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,920.0 Cr | -0.1% | 1.7% | 45.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,160.0 Cr | -0.1% | -2.2% | 56.9% | Stock Analytics | |
| CIPLA | ₹118,917.0 Cr | 1.7% | 0.5% | 23.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,017.0 Cr | 5.7% | 12.4% | 18.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,997.1 Cr | -1.4% | 3.1% | 44.8% | Stock Analytics | |
MARKSANS PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MARKSANS PHARMA | -2.7% |
-1.7% |
97.1% |
| SENSEX | -5% |
0.6% |
9.2% |
You may also like the below Video Courses
